Abhijeet A. Aher

Mr. Abhijeet A. Aher

Pharmaceutical Quality Assurance, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule, Dhule, India
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TPTulshidas S. Patil*
Tulshidas S. Patil*
NGNayan A. Gujarathi
Nayan A. Gujarathi
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
HPHemal E. Pachpande
Hemal E. Pachpande
CSCharu Sharma
Charu Sharma
YGYogeeta Agrawal Goyal
Yogeeta Agrawal Goyal
Psoriasis is linked with unusual differentiation and hyperproliferation of epidermal keratinocytes that significantly impair the quality of life (QoL) of patients. The present treatment options only provide symptomatic relief and are surrounded by various adverse effects. Recently, nanostructured lipid carriers (NLCs) have emerged as next-generation nanocarriers with better physicochemical characteristics. The current manuscript provides background information on psoriasis, its pathophysiology, existing treatment options, and its limitations. It highlights the advantages, rationale, and mechanism of the permeation of NLCs for the treatment of psoriasis. It further gives a detailed account of various NLC nanoformulations for the treatment of psoriasis. In addition, tabular information is provided on the most relevant patents on NLCs for treating psoriasis. Lastly, light is shed on regulatory considerations related to NLC-like nanoformulations. In the treatment of psoriasis, NLCs display a sustained release drug profile, an ability to incorporate both hydrophobic and hydrophilic drugs, an enhancement in skin hydration, penetrability, retention, and bioavailability of the drug, along with reduced staining potential as compared to conventional ointments, and decreased side effects of drug molecules. This affirms the bright future of NLC nanoformulations in the treatment of psoriasis. However, academic industry collaboration and more sound regulatory controls are required to commercialize the NLC nanoformulations for psoriasis treatment.

2 November 2015 in Analytical Chemistry Letters
Verified
Journal Article
Closed access
VRVikas G. Rajurkar
Vikas G. Rajurkar
SSShubhangi K. Somware
Shubhangi K. Somware
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
VPVarsha Pansare
Varsha Pansare
The improvement in the aqueous solubility, physicochemical and micromeritics property of insoluble and slightly soluble drugs is of major concern in pharmaceutical formulations. It is commonly observed in the durg industry that on average more than 35 % of newly discovered drugs are poorly water-soluble. Poor “drug like” properties of lead compounds led to ineffective absorption from the site of administration, less bioavailability which has been designated as an important part of the high clinical failure. In the present work, Carisoprodol, centrally acting skeletal muscle relaxant belongs to BCS class II drug (highly permeable and low soluble). A simultaneous differential scanning calorimetry (DSC), Fourier transforms infrared (FT-IR), XRPD microspectroscopy, SEM, dissolution study and micromeritics properties study was used to quickly investigate the co-crystal. Tablet formulation was developed by direct compression method and there evaluation was performed.

20 June 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
TKTanaya D. Khairnar
Tanaya D. Khairnar
GCGaurav S. Chavan
Gaurav S. Chavan
MSMeenaz M. Sayyed
Meenaz M. Sayyed
NGNayan A. Gujarathi
Nayan A. Gujarathi
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
TPTulshidas S. Patil*
Tulshidas S. Patil*

11 October 2012 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SDSwapnil S. Desai
Swapnil S. Desai
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
PKPreeti T. Kadaskar
Preeti T. Kadaskar
Dry powder inhaler (DPI) has become a well accepted drug delivery for pulmonary system to treat many related diseases including symptomatic and life threatening diseases. Successful delivery of dry powder to the lung requires careful consideration of powder production process, formulation and inhaler device. The formulation of DPI mostly comprises of lactose as a carrier for drug delivery. In DPI formulation, particulate interactions within the formulation govern both the drug dissociation from carrier particles and the disaggregation of drug into primary particles with a capacity to penetrate deep into lung. Two contradictory requirements must be fulfilled for this type of dry powder formulation. On one hand, adhesion between carrier and drug must be sufficient for the blend drug/carrier to be stable. On the other hand, adhesion drug/carrier has to be weak enough to enable the release of drug from carrier during patient inhalation. Thus the carrier use restricted due to detachment problem. Different methods are proposed to reduce the cohesive forces between drug and carrier to desired level. Various studies conducted for understanding the mechanism of deposition into lungs and making formulation with optimum carrier drug cohesive force. This review provides information on various processes involved in reducing the cohesive forces between drug and carrier, to a required level.


14 June 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NGNayan A. Gujarathi
Nayan A. Gujarathi
RGRushikesh Girase
Rushikesh Girase
ASAmey Sukhia
Amey Sukhia
Abhijeet A. AherAbhijeet A. Aher
Abhijeet A. Aher
TPTulshidas S. Patil*
Tulshidas S. Patil*
SKSri Sai Nikitha Kota
Sri Sai Nikitha Kota